Kazuki Nozawa, MD· @kazuki_nozawa · X·· 23 小时前评分70
正文 · 原文
KEYNOTE-B49
#ESMO26
Pembrolizumab + chemotherapy improved PFS in PD-L1+ HR+/HER2− advanced breast cancer (HR 0.74), with greater benefit in CPS ≥10 (HR 0.59). No significant OS or overall ORR benefit. Immune-mediated AEs were more frequent.
58 浏览 · 2 赞 · 0 转发 · 0 回复
会议摘要
LBA51按 Proffered paper 2: Breast cancer, early and advanced stage 对上
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)
https://esmocongress.esmo.org来源：Kazuki Nozawa, MD · x.com